Dosing & Uses
Dosage Forms & Strengths
tablet
- 5mg
- 7.5mg
- 10mg
capsule, extended-release
- 15mg
- 30mg
Muscle Spasm
Immediate-release tablet
- 5 mg PO q8hr; may increase dose to 7.5-10 mg PO q8hr PRN
Extended-release capsule
- 15 mg PO qDay; some patients may require up to 30 mg PO qDay
Dosing Modifications
Hepatic impairment
- Immediate-release tablet: 5 mg/day PO initially; titrate slowly and consider less frequent dosing
- Extended-release capsule: Not recommended in mild-to-severe hepatic impairment
Renal Impairment
- Not studied
Dosage Forms & Strengths
tablet
- 5mg
- 7.5mg
- 10mg
Muscle Spasm
Immediate-release tablet
- <15 years: Safety and efficacy not established
- >15 years: 5 mg PO q8hr; may increase dose to 7.5-10 mg PO q8hr PRN
Extended-release capsule
- <18 years: Safety and efficacy not established
- >18 years: 15 mg PO qDay; some patients may require up to 30 mg PO qDay
Muscle Spasm
Immediate-release tablet: 5 mg/day PO initially; titrate slowly upward and consider less frequent dosing
Extended-release capsule not recommended in elderly, because of increased plasma levels (40%) and prolonged half-life (56%) compared with young adults
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (4)
- isocarboxazid
isocarboxazid and cyclobenzaprine both increase serotonin levels. Contraindicated. Do not coadminister cyclobenzaprine with MAOIs or within 14 days of discontinuing an MAOI
- phenelzine
phenelzine and cyclobenzaprine both increase serotonin levels. Contraindicated. Do not coadminister cyclobenzaprine with MAOIs or within 14 days of discontinuing an MAOI
- safinamide
cyclobenzaprine, safinamide. Either increases toxicity of the other by serotonin levels. Contraindicated. Concomitant use could result in life-threatening serotonin syndrome.
- tranylcypromine
tranylcypromine and cyclobenzaprine both increase serotonin levels. Contraindicated. Do not coadminister cyclobenzaprine with MAOIs or within 14 days of discontinuing an MAOI
Serious - Use Alternative (51)
- abametapir
abametapir will increase the level or effect of cyclobenzaprine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP1A2 substrates. If not feasible, avoid use of abametapir.
- almotriptan
almotriptan and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- amitriptyline
amitriptyline and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- amoxapine
amoxapine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen, cyclobenzaprine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- bupropion
bupropion and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- calcium/magnesium/potassium/sodium oxybates
cyclobenzaprine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- citalopram
citalopram and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- clomipramine
clomipramine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- desipramine
desipramine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- desvenlafaxine
desvenlafaxine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- doxepin
doxepin and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- duloxetine
duloxetine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- eletriptan
eletriptan and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- escitalopram
escitalopram and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- fluoxetine
fluoxetine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- fluvoxamine
fluvoxamine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- frovatriptan
frovatriptan and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- givosiran
givosiran will increase the level or effect of cyclobenzaprine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP1A2 substrates with givosiran. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling.
- hydrocodone
hydrocodone, cyclobenzaprine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- imipramine
imipramine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- levomilnacipran
levomilnacipran and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- linezolid
linezolid and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first
- meperidine
meperidine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- methylene blue
methylene blue and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first
- metoclopramide intranasal
cyclobenzaprine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- milnacipran
milnacipran and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- mirtazapine
mirtazapine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- naratriptan
naratriptan and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- nefazodone
nefazodone and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- nortriptyline
nortriptyline and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- olopatadine intranasal
cyclobenzaprine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- paroxetine
paroxetine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- pramlintide
pramlintide, cyclobenzaprine. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.
- protriptyline
protriptyline and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- rizatriptan
rizatriptan and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- sertraline
sertraline and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- sodium oxybate
cyclobenzaprine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- sufentanil SL
sufentanil SL, cyclobenzaprine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- sumatriptan
sumatriptan and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- sumatriptan intranasal
sumatriptan intranasal and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- tedizolid
tedizolid, cyclobenzaprine. Either increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome.
- tramadol
tramadol and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- trazodone
trazodone and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- trimipramine
trimipramine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- vandetanib
cyclobenzaprine, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.
- venlafaxine
venlafaxine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- verapamil
verapamil and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- vilazodone
vilazodone and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- vortioxetine
cyclobenzaprine, vortioxetine. Either increases effects of the other by serotonin levels. Avoid or Use Alternate Drug.
- zolmitriptan
zolmitriptan and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
Monitor Closely (220)
- abobotulinumtoxinA
cyclobenzaprine increases effects of abobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.
- aclidinium
cyclobenzaprine and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- alfentanil
cyclobenzaprine and alfentanil both increase sedation. Use Caution/Monitor.
- alprazolam
alprazolam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- amantadine
cyclobenzaprine, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.
- amitriptyline
cyclobenzaprine and amitriptyline both increase sedation. Use Caution/Monitor.
- amobarbital
amobarbital and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- amoxapine
cyclobenzaprine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and amoxapine both increase sedation. Use Caution/Monitor. - anticholinergic/sedative combos
anticholinergic/sedative combos and cyclobenzaprine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- apomorphine
cyclobenzaprine and apomorphine both increase sedation. Use Caution/Monitor.
- aripiprazole
cyclobenzaprine and aripiprazole both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
aripiprazole increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - atracurium
atracurium and cyclobenzaprine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine
atropine and cyclobenzaprine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine IV/IM
atropine IV/IM and cyclobenzaprine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- azelastine
azelastine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- baclofen
baclofen and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- belladonna alkaloids
belladonna alkaloids and cyclobenzaprine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna and opium
cyclobenzaprine and belladonna and opium both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and belladonna and opium both increase sedation. Use Caution/Monitor. - benperidol
cyclobenzaprine and benperidol both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.
benperidol increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - benzphetamine
cyclobenzaprine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- benztropine
benztropine and cyclobenzaprine both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use.
- bethanechol
bethanechol increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- brexanolone
brexanolone, cyclobenzaprine. Either increases toxicity of the other by sedation. Use Caution/Monitor.
- brompheniramine
brompheniramine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- buprenorphine
cyclobenzaprine and buprenorphine both increase sedation. Use Caution/Monitor.
- buprenorphine buccal
cyclobenzaprine and buprenorphine buccal both increase sedation. Use Caution/Monitor.
- buprenorphine subdermal implant
cyclobenzaprine, buprenorphine subdermal implant. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.
- buprenorphine, long-acting injection
cyclobenzaprine, buprenorphine, long-acting injection. Either increases toxicity of the other by serum potassium. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.
buprenorphine, long-acting injection increases effects of cyclobenzaprine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and increase risk for respiratory depression. Monitor for signs of respiratory depression that may be greater than otherwise expected and decrease muscle relaxant dosage as necessary. - butabarbital
butabarbital and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- butalbital
butalbital and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- butorphanol
cyclobenzaprine and butorphanol both increase sedation. Use Caution/Monitor.
- cannabidiol
cannabidiol, cyclobenzaprine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition with the coadministration of CYP1A2 substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate.
- carbachol
carbachol increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carbinoxamine
carbinoxamine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- carisoprodol
carisoprodol and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- cenobamate
cenobamate, cyclobenzaprine. Either increases effects of the other by sedation. Use Caution/Monitor.
- cevimeline
cevimeline increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chloral hydrate
chloral hydrate and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
chlordiazepoxide and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- chlorpheniramine
chlorpheniramine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- chlorpromazine
cyclobenzaprine and chlorpromazine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.
chlorpromazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - cinnarizine
cinnarizine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- cisatracurium
cisatracurium and cyclobenzaprine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- citalopram
cyclobenzaprine and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
- clemastine
clemastine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- clobazam
cyclobenzaprine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
- clomipramine
cyclobenzaprine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and clomipramine both increase sedation. Use Caution/Monitor. - clonazepam
clonazepam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- clorazepate
clorazepate and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- clozapine
cyclobenzaprine and clozapine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.
clozapine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - codeine
cyclobenzaprine and codeine both increase sedation. Use Caution/Monitor.
- crizotinib
crizotinib and cyclobenzaprine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
- cyclizine
cyclizine and cyclobenzaprine both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclizine and cyclobenzaprine both increase sedation. Use Caution/Monitor. - cyproheptadine
cyproheptadine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- dantrolene
cyclobenzaprine and dantrolene both increase sedation. Use Caution/Monitor.
- daridorexant
cyclobenzaprine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- darifenacin
cyclobenzaprine and darifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- deferasirox
deferasirox will increase the level or effect of cyclobenzaprine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.
- desipramine
cyclobenzaprine and desipramine both increase sedation. Use Caution/Monitor.
- dexchlorpheniramine
dexchlorpheniramine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- dexfenfluramine
cyclobenzaprine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexmedetomidine
dexmedetomidine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- dextroamphetamine transdermal
cyclobenzaprine, dextroamphetamine transdermal. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s).
- dextromoramide
cyclobenzaprine and dextromoramide both increase sedation. Use Caution/Monitor.
- diamorphine
cyclobenzaprine and diamorphine both increase sedation. Use Caution/Monitor.
- diazepam
diazepam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- diazepam intranasal
diazepam intranasal, cyclobenzaprine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- dicyclomine
cyclobenzaprine and dicyclomine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- difelikefalin
difelikefalin and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- difenoxin hcl
cyclobenzaprine and difenoxin hcl both increase sedation. Use Caution/Monitor.
- dimenhydrinate
dimenhydrinate and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- diphenhydramine
cyclobenzaprine and diphenhydramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
diphenhydramine and cyclobenzaprine both increase sedation. Use Caution/Monitor. - diphenoxylate hcl
cyclobenzaprine and diphenoxylate hcl both increase sedation. Use Caution/Monitor.
- dipipanone
cyclobenzaprine and dipipanone both increase sedation. Use Caution/Monitor.
- donepezil
donepezil increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- donepezil transdermal
cyclobenzaprine, donepezil transdermal. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.
- dopexamine
cyclobenzaprine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dosulepin
cyclobenzaprine and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and dosulepin both increase sedation. Use Caution/Monitor. - doxepin
cyclobenzaprine and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and doxepin both increase sedation. Use Caution/Monitor. - doxylamine
doxylamine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- droperidol
cyclobenzaprine and droperidol both increase sedation. Use Caution/Monitor.
droperidol, cyclobenzaprine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of V tach, fibrillation.
cyclobenzaprine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - echothiophate iodide
echothiophate iodide increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- esketamine intranasal
esketamine intranasal, cyclobenzaprine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- estazolam
estazolam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- ethanol
cyclobenzaprine and ethanol both increase sedation. Use Caution/Monitor.
- etomidate
etomidate and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- fenfluramine
cyclobenzaprine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fesoterodine
cyclobenzaprine and fesoterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- fexinidazole
fexinidazole will increase the level or effect of cyclobenzaprine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.
- flavoxate
cyclobenzaprine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- fluphenazine
cyclobenzaprine and fluphenazine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.
fluphenazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - flurazepam
flurazepam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- galantamine
galantamine increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ganaxolone
cyclobenzaprine and ganaxolone both increase sedation. Use Caution/Monitor.
- glycopyrrolate
cyclobenzaprine and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- glycopyrrolate inhaled
cyclobenzaprine and glycopyrrolate inhaled both decrease cholinergic effects/transmission. Use Caution/Monitor.
- haloperidol
cyclobenzaprine and haloperidol both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.
haloperidol increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - homatropine
cyclobenzaprine and homatropine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- huperzine A
huperzine A increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- hydromorphone
cyclobenzaprine and hydromorphone both increase sedation. Use Caution/Monitor.
- hydroxyzine
hydroxyzine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- hyoscyamine
cyclobenzaprine and hyoscyamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- hyoscyamine spray
cyclobenzaprine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- iloperidone
cyclobenzaprine and iloperidone both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.
iloperidone increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - imipramine
cyclobenzaprine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and imipramine both increase sedation. Use Caution/Monitor. - incobotulinumtoxinA
cyclobenzaprine, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.
- indacaterol, inhaled
indacaterol, inhaled, cyclobenzaprine. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.
- ipratropium
cyclobenzaprine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ketamine
ketamine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- ketotifen, ophthalmic
cyclobenzaprine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- lasmiditan
lasmiditan, cyclobenzaprine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- lemborexant
lemborexant, cyclobenzaprine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- levorphanol
cyclobenzaprine and levorphanol both increase sedation. Use Caution/Monitor.
- lofepramine
cyclobenzaprine and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and lofepramine both increase sedation. Use Caution/Monitor. - lofexidine
cyclobenzaprine and lofexidine both increase sedation. Use Caution/Monitor.
- loprazolam
loprazolam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- lorazepam
lorazepam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- lormetazepam
lormetazepam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- loxapine
cyclobenzaprine and loxapine both increase sedation. Use Caution/Monitor.
- loxapine inhaled
loxapine inhaled increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
cyclobenzaprine and loxapine inhaled both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. - lurasidone
lurasidone, cyclobenzaprine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
- maprotiline
cyclobenzaprine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and maprotiline both increase sedation. Use Caution/Monitor. - marijuana
cyclobenzaprine and marijuana both increase sedation. Use Caution/Monitor.
- meclizine
cyclobenzaprine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- melatonin
cyclobenzaprine and melatonin both increase sedation. Use Caution/Monitor.
- meperidine
cyclobenzaprine and meperidine both increase sedation. Use Caution/Monitor.
- meprobamate
cyclobenzaprine and meprobamate both increase sedation. Use Caution/Monitor.
- metaxalone
cyclobenzaprine and metaxalone both increase sedation. Use Caution/Monitor.
- methadone
cyclobenzaprine and methadone both increase sedation. Use Caution/Monitor.
- methocarbamol
cyclobenzaprine and methocarbamol both increase sedation. Use Caution/Monitor.
- methscopolamine
cyclobenzaprine and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- methylenedioxymethamphetamine
cyclobenzaprine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- midazolam
midazolam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- midazolam intranasal
midazolam intranasal, cyclobenzaprine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- mirtazapine
cyclobenzaprine and mirtazapine both increase sedation. Use Caution/Monitor.
- morphine
cyclobenzaprine and morphine both increase sedation. Use Caution/Monitor.
- motherwort
cyclobenzaprine and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
cyclobenzaprine and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
cyclobenzaprine and nabilone both increase sedation. Use Caution/Monitor.
- nalbuphine
cyclobenzaprine and nalbuphine both increase sedation. Use Caution/Monitor.
- neostigmine
neostigmine increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nortriptyline
cyclobenzaprine and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and nortriptyline both increase sedation. Use Caution/Monitor. - olanzapine
cyclobenzaprine and olanzapine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.
olanzapine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - oliceridine
oliceridine, cyclobenzaprine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
cyclobenzaprine increases toxicity of oliceridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics. - olodaterol inhaled
cyclobenzaprine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias
- ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)
ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) decreases effects of cyclobenzaprine by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Increase dose if clinically indicated .
- onabotulinumtoxinA
onabotulinumtoxinA and cyclobenzaprine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- opium tincture
cyclobenzaprine and opium tincture both increase sedation. Use Caution/Monitor.
- orphenadrine
cyclobenzaprine and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and orphenadrine both increase sedation. Use Caution/Monitor. - oxazepam
oxazepam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- oxybutynin
cyclobenzaprine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin topical
cyclobenzaprine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin transdermal
cyclobenzaprine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxycodone
cyclobenzaprine and oxycodone both increase sedation. Use Caution/Monitor.
- oxymorphone
cyclobenzaprine and oxymorphone both increase sedation. Use Caution/Monitor.
- paliperidone
cyclobenzaprine and paliperidone both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.
paliperidone increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - pancuronium
cyclobenzaprine and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- papaveretum
cyclobenzaprine and papaveretum both increase sedation. Use Caution/Monitor.
- papaverine
cyclobenzaprine and papaverine both increase sedation. Use Caution/Monitor.
- pentazocine
cyclobenzaprine and pentazocine both increase sedation. Use Caution/Monitor.
- pentobarbital
pentobarbital and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- perphenazine
cyclobenzaprine and perphenazine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.
perphenazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - phenobarbital
phenobarbital and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- phenylephrine PO
cyclobenzaprine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pholcodine
cyclobenzaprine and pholcodine both increase sedation. Use Caution/Monitor.
- physostigmine
physostigmine increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pilocarpine
pilocarpine increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pimozide
cyclobenzaprine and pimozide both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.
pimozide increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - prabotulinumtoxinA
cyclobenzaprine increases effects of prabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.
- pralidoxime
cyclobenzaprine and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.
- primidone
primidone and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- prochlorperazine
cyclobenzaprine and prochlorperazine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - promethazine
promethazine and cyclobenzaprine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.
promethazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - propantheline
cyclobenzaprine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- propofol
propofol and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- propylhexedrine
cyclobenzaprine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- protriptyline
cyclobenzaprine and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and protriptyline both increase sedation. Use Caution/Monitor. - pyridostigmine
pyridostigmine increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- quazepam
quazepam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- quetiapine
cyclobenzaprine and quetiapine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.
quetiapine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
quetiapine, cyclobenzaprine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT. - ramelteon
cyclobenzaprine and ramelteon both increase sedation. Use Caution/Monitor.
- rapacuronium
cyclobenzaprine and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- rasagiline
rasagiline and cyclobenzaprine both increase serotonin levels. Modify Therapy/Monitor Closely.
- remifentanil
cyclobenzaprine increases effects of remifentanil by pharmacodynamic synergism. Modify Therapy/Monitor Closely. CNS depressant effect increased.
- remimazolam
remimazolam, cyclobenzaprine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
- rilpivirine
rilpivirine increases toxicity of cyclobenzaprine by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.
- risperidone
cyclobenzaprine and risperidone both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.
risperidone increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - rocuronium
cyclobenzaprine and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- rucaparib
rucaparib will increase the level or effect of cyclobenzaprine by affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP1A2 substrates, if clinically indicated.
- scopolamine
cyclobenzaprine and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- scullcap
cyclobenzaprine and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
secobarbital and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- selegiline
selegiline and cyclobenzaprine both increase serotonin levels. Modify Therapy/Monitor Closely.
- selegiline transdermal
selegiline transdermal and cyclobenzaprine both increase serotonin levels. Modify Therapy/Monitor Closely.
- shepherd's purse
cyclobenzaprine and shepherd's purse both increase sedation. Use Caution/Monitor.
- solifenacin
cyclobenzaprine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- stiripentol
stiripentol, cyclobenzaprine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP1A2 inhibitor and inducer. Monitor CYP1A2 substrates coadministered with stiripentol for increased or decreased effects. CYP1A2 substrates may require dosage adjustment.
stiripentol, cyclobenzaprine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence. - succinylcholine
succinylcholine increases and cyclobenzaprine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- sufentanil
cyclobenzaprine and sufentanil both increase sedation. Use Caution/Monitor.
- tapentadol
cyclobenzaprine and tapentadol both increase sedation. Use Caution/Monitor.
cyclobenzaprine and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely. - temazepam
temazepam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- teriflunomide
teriflunomide decreases levels of cyclobenzaprine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.
- thioridazine
cyclobenzaprine and thioridazine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.
thioridazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - thiothixene
cyclobenzaprine and thiothixene both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.
thiothixene increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - tiotropium
cyclobenzaprine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- tolterodine
cyclobenzaprine and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- topiramate
cyclobenzaprine and topiramate both increase sedation. Modify Therapy/Monitor Closely.
- tramadol
cyclobenzaprine and tramadol both increase sedation. Use Caution/Monitor.
- trazodone
cyclobenzaprine and trazodone both increase sedation. Use Caution/Monitor.
- triazolam
triazolam and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- triclofos
triclofos and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- trifluoperazine
cyclobenzaprine and trifluoperazine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.
trifluoperazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - trihexyphenidyl
cyclobenzaprine and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.
- trimipramine
cyclobenzaprine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and trimipramine both increase sedation. Use Caution/Monitor. - trospium chloride
cyclobenzaprine and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.
- vecuronium
cyclobenzaprine and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- xylometazoline
cyclobenzaprine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziconotide
cyclobenzaprine and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
cyclobenzaprine and ziprasidone both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.
ziprasidone increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - zotepine
cyclobenzaprine and zotepine both increase sedation. Use Caution/Monitor.
cyclobenzaprine decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
cyclobenzaprine decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.
Minor (7)
- desipramine
cyclobenzaprine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- dimenhydrinate
dimenhydrinate increases toxicity of cyclobenzaprine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- donepezil
donepezil decreases effects of cyclobenzaprine by pharmacodynamic antagonism. Minor/Significance Unknown.
- eucalyptus
cyclobenzaprine and eucalyptus both increase sedation. Minor/Significance Unknown.
- galantamine
galantamine decreases effects of cyclobenzaprine by pharmacodynamic antagonism. Minor/Significance Unknown.
- sage
cyclobenzaprine and sage both increase sedation. Minor/Significance Unknown.
- trazodone
cyclobenzaprine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
Adverse Effects
>10%
Drowsiness (up to 39% immediate-release; 100% extended-release)
Dry mouth (21-32%)
Dizziness (3-11%)
1-10%
Pharyngitis (1-3%)
Headache (1-5%)
Fatigue (6%)
Palpitations (6%)
Bad taste in mouth (1-6%)
Indigestion (4%)
Blurred vision (3%)
Constipation (1-3%)
Asthenia (1-3%)
Confusion (1-3%)
Nausea (1-3%)
Nervousness (1-3%)
<1%
Arrhythmia
Hypotension
Palpitation
Syncope
Tachycardia
Vasodilation
Cardiac dysrhythmia (rare)
Cholestasis (rare)
Hepatitis
Jaundice
Anaphylaxis (rare)
Immune hypersensitivity reaction
Postmarketing Reports
Serotonin syndrome
Hypertension
Stroke
Heart block
Myocardial infarction
Warnings
Contraindications
Hypersensitivity to drug or formulation components
Hyperthyroidism
During the acute recovery phase of myocardial infarction and in patients with arrhythmia, heart block or conduction disturbances, or congestive heart failure
Concomitant use or within 14 days of discontinuing MAO inhibitors
Hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors
Cautions
Use only for short periods (2-3 wk)
Use caution in urinary retention, narrow-angle glaucoma or IOP, or concomitant use of other anticholinergic drugs
May cause drowsiness/dizziness; do not ingest alcohol or other CNS depressants; may impair ability to operate heavy machinery
May take with food to avoid stomach upset
Serotonin syndrome reported when coadministered with other drugs that increase serotonin (eg, SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [see also Contraindications])
Not effective for treatment of spasticity associated with cerebral/spinal cord disease or for pediatric cerebral palsy
Elderly patients may be more prone to adverse effects and require dose/frequency reduction
Use immediate release with caution in hepatic impairment; extended-release form not recommended with hepatic impairment
Pregnancy & Lactation
Pregnancy
Available data from case reports with use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
Animal data
- In rats, decreased pup body weight and survival was noted at cyclobenzaprine doses ≥10 mg/kg/day (approximately ≥3 times maximum recommended human dose (MRHD) of 30 mg/day), when administered orally during pregnancy and lactation
Lactation
There are no data on presence of drug in either human or animal milk, the effects on a breastfed infant, or effects on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Relieves local skeletal muscle spasm; clinical response similar to diazepam
Structurally related to cyclic antidepressants, and pharmacologic effects are similar, including reserpine antagonism, norepinephrine potentiation, potent peripheral and central anticholinergic effects, and sedation; reduces tonic somatic motor activity influencing alpha and gamma motor neurons
Absorption
Onset: 1 hr
Duration: 12-24 hr
Bioavailability: 33-55%
Peak plasma time: 7-8 hr
Peak plasma concentration: 15-25 ng/mL
Distribution
Protein bound: 93%
Metabolism
Hepatic via CYP3A4, 1A2, and 2D6; may undergo enterohepatic recirculation
Elimination
Half-life: 8-37 hours (immediate release); 32-33 hr (extended release)
Excretion: Urine, feces
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| cyclobenzaprine oral - | 5 mg tablet |  | |
| cyclobenzaprine oral - | 5 mg tablet |  | |
| cyclobenzaprine oral - | 10 mg tablet |  | |
| cyclobenzaprine oral - | 5 mg tablet |  | |
| cyclobenzaprine oral - | 10 mg tablet |  | |
| cyclobenzaprine oral - | 10 mg tablet |  | |
| cyclobenzaprine oral - | 7.5 mg tablet |  | |
| cyclobenzaprine oral - | 7.5 mg tablet |  | |
| cyclobenzaprine oral - | 15 mg capsule |  | |
| cyclobenzaprine oral - | 10 mg tablet |  | |
| cyclobenzaprine oral - | 10 mg tablet |  | |
| cyclobenzaprine oral - | 15 mg capsule |  | |
| cyclobenzaprine oral - | 7.5 mg tablet |  | |
| cyclobenzaprine oral - | 7.5 mg tablet |  | |
| cyclobenzaprine oral - | 10 mg tablet |  | |
| cyclobenzaprine oral - | 10 mg tablet |  | |
| cyclobenzaprine oral - | 5 mg tablet |  | |
| cyclobenzaprine oral - | 5 mg tablet |  | |
| cyclobenzaprine oral - | 30 mg capsule |  | |
| cyclobenzaprine oral - | 5 mg tablet |  | |
| cyclobenzaprine oral - | 5 mg tablet |  | |
| cyclobenzaprine oral - | 30 mg capsule |  | |
| cyclobenzaprine oral - | 10 mg tablet |  | |
| cyclobenzaprine oral - | 15 mg capsule |  | |
| cyclobenzaprine oral - | 30 mg capsule |  | |
| cyclobenzaprine oral - | 7.5 mg tablet |  | |
| cyclobenzaprine oral - | 10 mg tablet |  | |
| cyclobenzaprine oral - | 5 mg tablet |  | |
| cyclobenzaprine oral - | 30 mg capsule |  | |
| cyclobenzaprine oral - | 15 mg capsule |  | |
| cyclobenzaprine oral - | 10 mg tablet |  | |
| cyclobenzaprine oral - | 5 mg tablet |  | |
| cyclobenzaprine oral - | 7.5 mg tablet |  | |
| Fexmid oral - | 7.5 mg tablet |  | |
| Amrix oral - | 30 mg capsule | | |
| Amrix oral - | 15 mg capsule | |
Copyright © 2010 First DataBank, Inc.
Patient Handout
cyclobenzaprine oral
CYCLOBENZAPRINE - ORAL
(sye-klo-BENZ-uh-preen)
COMMON BRAND NAME(S): Flexeril
USES: Cyclobenzaprine is used short-term to treat muscle spasms. It is usually used along with rest and physical therapy. It works by helping to relax the muscles.
HOW TO USE: Take this medication by mouth with or without food as directed by your doctor. Do not increase your dose or use this drug more often or for longer than prescribed. Your condition will not improve any faster, and your risk of side effects will increase.The dosage is based on your medical condition and response to treatment. This medication should only be used short-term (for 3 weeks or less) unless directed by your doctor.ell your doctor if your condition lasts after 2 to 3 weeks or if it gets worse.
SIDE EFFECTS: Drowsiness, dizziness, dry mouth, constipation, or tiredness may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: fast/irregular heartbeat, mental/mood changes (such as confusion, hallucinations), trouble urinating.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking cyclobenzaprine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease, overactive thyroid (hyperthyroidism), heart problems (such as irregular heartbeat, heart block, heart failure, recent heart attack), difficulty urinating (such as due to an enlarged prostate), glaucoma.This drug may make you dizzy or drowsy. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially drowsiness, confusion, constipation, or trouble urinating. Drowsiness and confusion can increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this medication passes into breast milk. However, similar drugs pass into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: tricyclic antidepressants (such as amitriptyline, imipramine).Taking MAO inhibitors with this medication may cause a serious (possibly fatal) drug interaction. Avoid taking MAO inhibitors (isocarboxazid, linezolid, metaxalone, methylene blue, moclobemide, phenelzine, procarbazine, rasagiline, safinamide, selegiline, tranylcypromine) during treatment with this medication. Most MAO inhibitors should also not be taken for two weeks before treatment with this medication. Ask your doctor when to start or stop taking this medication.Before using this medication, report the use of drugs that increase serotonin, including street drugs (such as MDMA/"ecstasy"), St. John's wort, certain antidepressants (including SSRIs such as fluoxetine/paroxetine, SNRIs such as duloxetine/venlafaxine), tramadol, among others.Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), other muscle relaxants (such as carisoprodol, methocarbamol), or antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: fast/irregular heartbeat, fainting, severe drowsiness, trouble speaking, seizures, mental/mood changes (such as confusion, hallucinations).
NOTES: Do not share this medication with others.This medication has been prescribed for your current condition only. Do not use it later for another condition unless your doctor directs you to do so. A different medication may be necessary in that case.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised May 2022. Copyright(c) 2022 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
